Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
Calcium (carbonate, citrate, gluconate, chloride salts) (1) ·
Fluorouracil (5-FU) (1) ·
Ivermectin (1) ·
Levetiracetam (1) ·
Magnesium (oxide, citrate, sulfate, hydroxide, gluconate, chloride salts) (1) ·
Oxcarbazepine (1) ·
Riboflavin (vitamin B2) (1) ·
Tretinoin (all-trans retinoic acid, ATRA) (1)
Efudex (topical), Carac (topical), Fluoroplex (topical); generic IV (1) ·
Keppra (IR), Keppra XR, Spritam (3D-printed orally disintegrating), Roweepra (1) ·
Mag-Ox, Slow-Mag, MagCitrate, Milk of Magnesia (hydroxide); IV sulfate generic (1) ·
Many generics/OTC (1) ·
Retin-A, Renova, Atralin, Avita, Tretin-X, Refissa, Altreno; Vesanoid (oral, APL) (1) ·
Stromectol (oral, generic), Sklice (lice, topical), Soolantra (rosacea, topical 1%) (1) ·
Trileptal (IR), Oxtellar XR (1) ·
Tums, Caltrate, Os-Cal, Citracal; many generics (1)
APL)]] (1) ·
hydroxide)]] (1) ·
torsades)]] (1) ·
[[:Category:Antacids|Antacid (carbonate)]] (1) ·
[[:Category:Antacids|Antacid (hydroxide)]] (1) ·
[[:Category:Antiarrhythmics|Antiarrhythmic (IV sulfate (1) ·
[[:Category:Anticonvulsants|Anticonvulsant]] (2) ·
[[:Category:Antimetabolites|Antimetabolite (pyrimidine analog)]] (1) ·
[[:Category:Antineoplastics|Antineoplastic (oral (1) ·
[[:Category:Antineoplastics|Antineoplastic]] (1) ·
[[:Category:Antiparasitics|Antiparasitic]] (1) ·
[[:Category:B-vitamins|B-vitamin]] (1) ·
[[:Category:Calcium_supplements|Calcium supplement]] (1) ·
[[:Category:Electrolyte_replacements|Electrolyte replacement]] (2) ·
[[:Category:Macrocyclic_lactones|Macrocyclic lactone (avermectin)]] (1) ·
[[:Category:Mood stabilizers|Mood stabilizer (off-label)]] (1) ·
[[:Category:Osmotic_laxatives|Osmotic laxative (citrate (1) ·
[[:Category:Retinoids|Retinoid]] (1) ·
[[:Category:Sodium channel blockers|Sodium channel blocker]] (1) ·
[[:Category:SV2A ligands|Synaptic vesicle protein 2A (SV2A) ligand]] (1) ·
[[:Category:Topical_retinoids|Topical retinoid]] (1) ·
[[:Category:Vitamins|Vitamin]] (1)
None (6) ·
'"`UNIQ--vote-0000124C-QINU`"' The 400 mg/d dose for migraine prophylaxis is supported by randomized trials (Schoenen 1998) and remains a low-risk evidence-based supplement option. Characteristic bright-yellow urine fluorescence with high-dose oral supplementation. (1) ·
'"`UNIQ--vote-00001302-QINU`"' Renally cleared; accumulation in advanced CKD can produce neuromuscular and cardiac depression. Hypomagnesemia frequently co-exists with hypokalemia and is often the reason refractory potassium loss does not correct until magnesium is repleted. (1)
'"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"' (1) ·
'"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"' (1) ·
'"`UNIQ--vote-00000BA0-QINU`"', '"`UNIQ--vote-00000BA1-QINU`"', '"`UNIQ--vote-00000BA2-QINU`"' (1) ·
'"`UNIQ--vote-0000108C-QINU`"', '"`UNIQ--vote-0000108D-QINU`"', '"`UNIQ--vote-0000108E-QINU`"', '"`UNIQ--vote-0000108F-QINU`"', '"`UNIQ--vote-00001090-QINU`"', '"`UNIQ--vote-00001091-QINU`"' (1) ·
'"`UNIQ--vote-000011BA-QINU`"', '"`UNIQ--vote-000011BB-QINU`"', '"`UNIQ--vote-000011BC-QINU`"', '"`UNIQ--vote-000011BD-QINU`"' (1) ·
'"`UNIQ--vote-0000124D-QINU`"', '"`UNIQ--vote-0000124E-QINU`"', '"`UNIQ--vote-0000124F-QINU`"' (1) ·
'"`UNIQ--vote-000012B7-QINU`"', '"`UNIQ--vote-000012B8-QINU`"', '"`UNIQ--vote-000012B9-QINU`"', '"`UNIQ--vote-000012BA-QINU`"', '"`UNIQ--vote-000012BB-QINU`"' (1) ·
'"`UNIQ--vote-00001303-QINU`"', '"`UNIQ--vote-00001304-QINU`"', '"`UNIQ--vote-00001305-QINU`"', '"`UNIQ--vote-00001306-QINU`"', '"`UNIQ--vote-00001307-QINU`"', '"`UNIQ--vote-00001308-QINU`"', '"`UNIQ--vote-00001309-QINU`"' (1)
Adult monotherapy: 300 mg PO BID, titrate by 300 mg every 3 days. Pediatric: weight-based titration starting 8-10 mg/kg/day divided BID (1) ·
Adult: 500 mg PO BID, titrate by 1000 mg/day every 2 weeks. Pediatric: 10-20 mg/kg/day divided BID, weight-titrated (1) ·
Migraine prophylaxis: 400 mg PO daily; deficiency replacement 5-30 mg/d (1) ·
Oral: 1000-1500 mg elemental calcium/day in divided doses for supplementation; IV gluconate 1 g (4.65 mEq) over 5-10 min for hyperkalemia or symptomatic hypocalcemia (1) ·
Replacement oxide 400-800 mg/d in divided doses (high diarrhea rate); citrate 200-400 mg/d (better tolerated, better absorbed); IV sulfate 1-2 g over 5-60 minutes for hypomagnesemia or torsades; eclampsia 4-6 g IV loading then 1-2 g/h (1) ·
Strongyloides 200 mcg/kg PO single dose; scabies 200 mcg/kg PO repeated at 7-14 days; onchocerciasis 150 mcg/kg q6-12 months (1) ·
Topical: 0.5-5% cream/solution to lesions BID × 2-4 weeks; systemic IV: regimen-specific in cancer chemotherapy (1) ·
Topical: pea-sized amount to dry face at bedtime, building from 2-3×/week to nightly as tolerated; oral APL: 45 mg/m²/d in divided doses (1)
0.5% (Carac), 1% (Fluoroplex), 5% (Efudex) topical creams/solutions; 50 mg/mL IV (1) ·
25, 50, 100, 250, 400 mg tablets; OTC (1) ·
3 mg tablets (Stromectol); 0.5% topical lotion (Sklice); 1% topical cream (Soolantra) (1) ·
Carbonate 200, 400, 500, 600 mg elemental tablets and chewables; citrate 200, 250, 315 mg elemental; gluconate 1 g (94 mg elemental, 4.65 mEq) IV; chloride 1 g (270 mg elemental, 13.6 mEq) IV (1) ·
IR tablets 150, 300, 600 mg; oral suspension 60 mg/mL; XR tablets 150, 300, 600 mg (Oxtellar) (1) ·
IR tablets 250, 500, 750, 1000 mg; XR tablets 500, 750 mg; oral solution 100 mg/mL; injection 100 mg/mL; Spritam ODT 250, 500, 750, 1000 mg (1) ·
Oxide 400, 500 mg tablets (240, 300 mg elemental); citrate 100, 150, 200 mg tablets; hydroxide oral suspension 400 mg/5 mL; sulfate IV 500 mg/mL ampules (1) ·
Topical 0.01-0.1% creams, gels, micropsheres, lotions; oral 10 mg capsules (Vesanoid) (1)
2400 mg/day (adult) (1) ·
3000 mg/day (1) ·
Indication-specific; renal clearance limits tolerable cumulative dosing (1) ·
No strict ceiling for water-soluble vitamin; UL not set (1) ·
Single 200-400 mcg/kg per dose for systemic indications (1) ·
Topical: nightly; oral APL: 45 mg/m²/d (1) ·
Topical: nightly; systemic: regimen-specific (1) ·
~2500 mg elemental/d combined diet + supplements (chronic; UL) (1)
Acute: minutes (IV); chronic: bone effect over months (1) ·
Anticonvulsant effect within days at therapeutic plasma level (1) ·
Anticonvulsant effect within days at therapeutic plasma level; rapid titration possible (1) ·
Hours to days (1) ·
Migraine effect after 1-3 months of daily use (1) ·
Oral: hours; IV: minutes (1) ·
Topical: inflammation, erythema, crusting at 2 weeks; complete response weeks to months after course (1) ·
Topical: irritation within days; acne improvement 6-12 weeks; oral APL response within days (1)
6-8 hours'"`UNIQ--ref-0000001F-QINU`"' (1) ·
Not meaningfully described (electrolyte) (1) ·
Not meaningfully described (electrolyte; renally cleared) (1) ·
Oxcarbazepine 2 hours; '''10-monohydroxy active metabolite (MHD) ~9 hours''' (the agent that produces essentially all of the clinical effect)'"`UNIQ--ref-0000001A-QINU`"' (1) ·
~0.5-2 hours (oral)'"`UNIQ--ref-00000BA3-QINU`"' (1) ·
~1-2 hours plasma (riboflavin itself); FAD/FMN tissue cofactors are continuous (1) ·
~10-20 minutes systemically (rapid hepatic and erythrocyte dihydropyrimidine dehydrogenase clearance)'"`UNIQ--ref-000011BE-QINU`"' (1) ·
~16-18 hours'"`UNIQ--ref-00001092-QINU`"' (1)
Carbonate ~30-40% (best with food and acid); citrate ~24% (absorbable without acid; preferred in achlorhydria, PPI use, post-bariatric) (1) ·
Highly salt-dependent: citrate ~25-30%; oxide ~4% (limited and causes osmotic diarrhea); chloride ~12% (1) ·
Topical: minimal systemic absorption (oral systemic 5-FU not used due to poor and variable absorption)'"`UNIQ--ref-000011BF-QINU`"' (1) ·
Topical: minimal systemic absorption with normal skin; oral: variable, induced metabolism with repeated dosing'"`UNIQ--ref-00000BA4-QINU`"' (1) ·
~100% (oral)'"`UNIQ--ref-0000001B-QINU`"' (1) ·
~100% (oral)'"`UNIQ--ref-00000020-QINU`"' (1) ·
~50-60% (oral; food enhances) (1) ·
~60% (oral; substantially increased with high-fat meal)'"`UNIQ--ref-00001093-QINU`"' (1)
None (1) ·
'''Considered one of the safest anticonvulsants in pregnancy''', with reassuring monotherapy registry data comparable to lamotrigine and in sharp contrast to valproate, topiramate, and carbamazepine'"`UNIQ--ref-00000021-QINU`"' (1) ·
IV sulfate is the cornerstone of eclampsia/preeclampsia management; oral replacement also safe.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; risk-benefit case by case; pregnancy is not a strict contraindication in WHO mass drug administration programs.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Routinely supplemented in pregnancy; needs higher in pregnancy and lactation.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Safe at replacement and supplement doses.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Teratogenic signal less than carbamazepine but present; folate supplementation and effective contraception are appropriate in reproductive-age patients'"`UNIQ--ref-0000001C-QINU`"' (1) ·
Topical: avoid; systemic: contraindicated in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
OTC (oral salts) and [[USLegal:Prescription only|Rx-only]] (IV) in US (1) ·
OTC (oral supplements) and [[USLegal:Prescription only|Rx-only]] (IV) in US (1) ·
OTC in US (1) ·
[[USLegal:Prescription only|Rx-only]] in US (3) ·
[[USLegal:Prescription only|Rx-only]] in US (the veterinary preparations are not for human use) (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance'"`UNIQ--ref-00000022-QINU`"' (1)
Showing below up to 8 results in range #1 to #8.


